Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Woodford
He sends out "unicorn" article on twitter when NWBO gets a halt? Place your bets.
Are we the unicorn?
https://woodfordfunds.com/investment-catalyst-myth/
Great Question and answer video with Dr Missling.
http://stocknewsnow.com/commentary/ANEWSID28072015100001/$AVXL-Mid-Year-Review-2015-with-Anavex-Life-Sciences-Corp-
Good unbiased overview of AVXL
Good to see you too! Haven't sold a share. Upcoming catalysts are too important. This company with Dr Missling as CEO has really caught my attention as well. Will continue DD here and with Northwest GLTA ;)
Interview With Dr Christopher Missling, CEO Of Anavex Jul. 24, 2015 8:50 AM ET
http://seekingalpha.com/article/3354415-interview-with-dr-christopher-missling-ceo-of-anavex
VETS FIGHTINGBREAST CANCER
http://www.vetsfightingbreastcancer.com/Vaccine_Research_2.html
Army Col. (Dr.) George E. Peoples explains how cancer vaccines help to combat breast cancer during an interview at San Antonio Military Medical Center. Peoples, director and principal investigator for the Cancer Vaccine Development Program, has helped to develop a vaccine that’s offering breast cancer survivors hope for a cancer-free future.
Anavex Life Sciences Corp (OTCMKTS:AVXL) To Participate In AAIC Event
July 9, 2015 Steven Gray
Anavex Life Sciences Corp (OTCMKTS:AVXL) informed that it will participate in the upcoming event AAIC that will be held in Washington D.C. The event will start on June 18, 2015 wherein the company will present primary findings from its ongoing Phase II a trial of “ANAVEX 2-73.” The company is a clinical stage entity and is making efforts to innovate medications to cure fatal diseases including Alzheimer’s.
The multicenter study
In the recent PR, Anavex disclosed the outline of design plan of the ongoing Phase 2 a study. The company reported that it is going to be a multicenter trial which will be performed in two phases. The study will enroll 32 subjects and more suffering with Alzheimer’s disease. The first stage of the study will be a simple. Two-period, adaptive, open-label randomized and cross over trial. During the first stage, the patients will be dosed with drug for 36 days.
After the completion of first stage, Anavex Pharma will start with the second part of trial wherein the subjects will be dosed with the drug for another twenty-six weeks. It is planned to evaluate the impact and efficacy of the drug on the subjects who wish to become a part of extended trial.
The therapy
The main objective of the study carried out by Anavex Life is to assess the MTD of ‘ANAVEX 2-73’ in patients with Alzheimer’s. Once MTD is known, the company will then assess various other elements including drug response, exploratory cognitive effectiveness and bioavailability. Anavex 2-73 is in a Phase 2a clinical study for Alzheimer and has already passed Phase I study with a clean data profile. Preclinical trials showed its potential to reverse or stop the course of Alzheimer’s disease.
Anavex Life Sciences Corp (OTCMKTS:AVXL) suffered a sharp loss of 7.55% in the last trading session but it would still be hard to conclude that the uptrend was finished. The rally from the June bottom showed a bit of bullish acceleration and only a break below $0.40 may endanger the bulls in the short to medium term. The rally is old and the state is overbought, inviting frequent corrections. The volume of the last session printed 3 million against the daily average of 2.3 million, suggesting some selling pressure. The bulls would like to avoid a weekly closing below $0.45.
http://stocksntrade.com/wp-content/uploads/2015/07/AVXL4.jpg
Anavex Life Sciences Corp (OTCMKTS:AVXL) suffered a sharp loss of 7.55% in the last trading session but it would still be hard to conclude that the uptrend was finished. The rally from the June bottom showed a bit of bullish acceleration and only a break below $0.40 may endanger the bulls in the short to medium term. The rally is old and the state is overbought, inviting frequent corrections. The volume of the last session printed 3 million against the daily average of 2.3 million, suggesting some selling pressure. The bulls would like to avoid a weekly closing below $0.45.
Northwest Biotherapeutics: The Perfect Storm May Be Brewing for Short Sellers POSTED by LARRY SMITH on JUN 16, 2014
One of my favorite blogs from Larry..
http://smithonstocks.com/northwest-biotherapeutics-the-perfect-storm-may-be-brewing-for-short-sellers-nwbo-7-66-buy-free-content/
"I think that there is the potential for a major short squeeze given all of these events and how strung out the shorts are. I would also add that hedge funds are like sharks in a feeding frenzy and if other hedge funds see the hedge funds currently short the stock getting squeezed, they will jump in and exacerbate the squeeze. This is why I see a perfect storm building that could cause the stock to over react on the upside. This could create a difficult decision for long term investors but I will cross that bridge when we get to it."
I believe a year later we are finally crossing that bridge.
Congressman Fattah Pushes for Passage of Bipartisan 21st Century Cures Legislation in House
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.
SOURCE Office of Congressman Chaka Fattah
The law will offer innovative solutions to accelerate the discovery and delivery of new cures for disease
WASHINGTON, June 2, 2015 /PRNewswire-USNewswire/ -- Congressman Chaka Fattah (PA-02), a Senior Member of the Appropriations Subcommittee on Labor, Health and Human Services, and Education, applauded the unanimous passage of the 21st Century Cures Act by the House Energy and Commerce Committee. The bill, which could be voted on by the full House as early as this month, would accelerate the discovery, development, and delivery of 21st century cures for disease and disorders. Congressman Fattah is an original co-sponsor of the bill that was authored by Congressman Fred Upton (R-MI) and Congresswoman Dianna DeGette (D-CO).
"This is a significant piece of legislation that has vast implications for the health and well-being of every American and I am proud to be an original co-sponsor of the 21st Century Cures Act,"Congressman Fattah said. "There is no more important health challenge than discovering the cures to the thousands of diseases that inflict Americans every day. We know that we can have a more nimble, accelerated route that fosters innovation and research and brings these discoveries to patients quicker. This legislation comprehensively addresses these issues, while supplying much needed funding for the country's research agencies; I hope that I have a chance to join my colleagues on all sides of the aisle in passing this legislation through the House this month."
The bill's provisions include streamlining the Food and Drug Administration's (FDA) process for regulating healthcare products, increasing funding for the National Institutes of Health (NIH), prioritizing patient participation in research and drug approval practices, streamlining clinical trials, and modernizing medical product guidelines.
Congressman Fattah has been recognized as a leading Congressional advocate for funding medical research and innovation. He is architect of the Fattah Neuroscience Initiative that works to achieve groundbreaking progress in understanding the human brain by creating partnerships and collaborations to expand the scope of research, tools, support, and funding dedicated to finding cures and treatments for brain disease and disorders. Additionally, he has introduced legislation, America's FOCUS Act, which would bring unprecedented sums of money to NIH to support innovations in medical research and development.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/congressman-fattah-pushes-for-passage-of-bipartisan-21st-century-cures-legislation-in-house-300092738.html
Elizabeth A. Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses nelipepimut-S (NeuVax) and a proposed trial for patients with ductal carcinoma in situ (DCIS).
Mittendorf has been involved with the development of nelipepimut-S, an immunodominant nonapeptide that will now be examined in the phase III PRESENT trial for patients with low to intermediate HER2 expression. Nelipepimut-S was also tested in phase I/II studies and was found to be safe and effective, eliciting an immune response, Mittendorf explains.
The vaccine was administered to patients with breast cancer who were found to be disease-free with standard of care therapy, with a purpose to prevent disease recurrence. Enrolled patients, who were at a 20% risk of disease recurrence, were at a 10% risk following treatment with nelipepimut-S.
A proposed trial will examine nelipepimut-S in the adjuvant setting for patients with DCIS. Patients will be vaccinated prior to surgery, and a blood test will determine if patients have an appropriate immune response, Mittendorf says. - See more at:
http://www.onclive.com/conference-coverage/aacr-2015/Dr-Mittendorf-on-Nelipepimut-S-in-Breast-Cancer#sthash.UDa3Hda2.N70uoD4m.dpuf
2015 AACR Meeting
Elizabeth A. Mittendorf, MD, PhD Published Online: Tuesday, April 21, 2015
ESPN not top 10 plays of the week.
"The assertion, especially as a "fact", that someone who invests nearly $70 million in a small, thinly traded biotech in two tranches some time apart not only cares what the price may be in a few months, but cares enough to buy a huge amount of puts as a hedge... well, that's simply laughable."
I was thinking how funny that statement was myself and it would definitely make my NOT top 10 plays of the week.
1 week from tonight:
World Vaccine Congress 2015, Washington D.C. - April 9, 2015, 10:25 a.m. ET - Linda Powers, CEO, NWBO
I think this will make my Top 10 plays of next week. ;) Just giving my POV!! Lets have more fun here and not be so brassy with our posts....these are all opinions until proven otherwise....just sayin.
Now time to watch some more hockey!!
Fall In Love With These 4 Biotech Stocks
http://www.wsobserver.com/fall-in-love-with-these-4-biotech-stocks-receptos-rcpt-northwest-biotherapeutics-nwbo-alnylam-pharmaceuticals-alny-merrimack-pharmaceuticals-mack/728258/
Northwest Biotherapeutics, Inc (NASDAQ:NWBO rose +5.21% to end last trading session at $7.67. The company, on March 27, 2015, released that Dr. Marnix Bosch, the Company’s Chief Technical Officer, presented encouraging survival data on 51 Glioblastoma multiforme (GBM) brain cancer patients treated with DCVax®-L. The data showed substantially longer than expected survival in patients with apparent early progression (recurrence) of their cancer, including patients with such aggressive cancer that the tumor was already re-growing by the end of 6 weeks of daily radiotherapy and chemotherapy after surgical removal of the original tumor.
I know we're not supposed to fall in love with stocks but I REALLY like this one! From The Wallstreet Observer. Like the new attention created from Germany
I vote we have CEO start and finish presentations and have clinical findings/body of conference given by a clinical MD. Make sense? Now implementation of the plan may take some doing lol!!
"Dr. Bosch would certainly get my call for all the presentations in the future though. He presents the info with a level of professionalism that IMO Linda doesn't. No catch phrase of "stay tuned" and "these patients are toast". Austinmediainc #31645
The first conference I listened to, LP spoke of the "special sauce" and I almost passed on this company. When I attend conferences for continuing education ( I'm a physician, GP ) and the speaker/lecturer is not an MD/physician that has seen patients in my field it can feel like I'm in the presence of a salesman. Future presentations from Dr. Bosch, Dr Lia or Dr Sabbiah I think would be more prudent... IMO of course
Nothing against Linda's presentations. ..I just personally prefer listening/learning from "hands on" speakers if that makes sense.
(Took 4 hrs to complete this little post in between pts and these dam popups!!!!lol)
'Id offer you advice, but I just don't care about your money, unless you give me money to care about your money. I might even be tricking you with the above post...
Now I get it!!! ;)
Amen!
That will be and has been my position since day one. Someone show me sound proof that fundamentals have changed.....I am "Staying Tuned" until they do. All else is speculation towards DCVax failure.
OT read for immunotherapy junkies...while we wait
http://seekingalpha.com/article/2978816-galena-biopharmas-gale-ceo-mark-schwartz-on-q4-2014-results-earnings-call-transcript
Not pushing stock, I do think article shows how immunotherapy companies are gaining traction especially with combination txs. Have a great weekend. Springbreak at the beach for us!!
The transparency/lack of PRs can be disconcerting, but I feel this has been done with a purpose as not to jeopardize the integrity of the trials. If you're familiar with GALE you know what can happen with "overloading" data to the shareholders. AF has hurt many companies in the past and I think (am trusting) that LP is in the best interests of the shareholders. We will know soon enough. ?? GLTU
You're correct Rkmatters. I think some of us need to remember what we're waiting for.....clinical results. All we have are earlier updates so it does not hurt to go back. :)
http://www.nwbio.com/dcvax-direct-trial-update-indicates-further-positive-responses-3-case-studies-show-no-live-tumor-cells-in-injected-tumors/
DCVax-Direct Trial Update Indicates Further Positive Responses; 3 Case Studies Show No Live Tumor Cells In Injected Tumors
All 9 Out Of 9 Patients Who Have Reached 4 Injections Are Showing Tumor Cell Death, Tumor Shrinkage And/Or Stabilization Of Disease
These are game changing results. We now need to know if they've improved (my prediction/speculation) on these numbers.
"STAY TUNED" LOL!!!!!
Afford, have you ever seen Stripes? After reading your rant all I could hear was "lighten up Frances"
Good idea.
Probably best to just post link and let people register. Hate to have Larry angry with us ??. SOS is one of my favorites.
He does usually post on SA as iclight has stated. GLTA
Just need to register....blogs are available to registered users. Full reports are Xtra
Immuno-Oncology Promises to be the Next “Big Thing” In Biotechnology
http://smithonstocks.com/recent-blogs/
Have a cup of coffee and enjoy. Great stuff again from SOS
"Expected to cost hundreds of thousands of dollars"
Lower cost AND more efficient treatments will ultimately prevail IMO.
http://www.bidnessetc.com/32800-kite-pharma-takes-cue-from-battle-between-gilead-gild-abbvie-abbv/
http://www.ft.com/intl/cms/s/2/5e0b1f54-9ca0-11e4-a730-00144feabdc0.html#ixzz3Ozls6J8b
Be patient with Northwest Biotherapeutics technology and I think you'll be fine. Stay tuned.....
Great stuff Smokey!
These articles seem to make a lot of people nervous. They just solidify my investment thinking with NWBO. Immunotherapy companies are going to be a household name in the future and the more research that comes out, the more we find DCVax has a better safety profile. Efficacy news is coming and NWBO'S name will be in articles like this soon IMO. How long before CNBC mentions NWBO? 3-6 mos???
http://www.cnbc.com/id/102336417
Pullback today on KITE and JUNO.
Let's have 2015 be a changing of the guards. Safety is a huge issue as you know with CAR-T immunotherapy. CEO admits this and they're EARLY in development.
http://finance.yahoo.com/video/junos-promising-car-t-immunotherapy-221500054.html
Stay tuned!! Lol I'm patiently waiting
Interesting comments from a aphillipo on yahoo. 1st I've heard about Heights Capital Management and am not well versed in warrants to make a rational thought on it...am at work so research is at a minimum for me now ?? Only enhances the AF controversial (or criminal!!) activity in biotechnology stocks.
Who are Heights Capital Management?
Adam Feuerstein disclosed the beneficiary of the last two US (gift wrapped) placings as Heights Capital Management before it was in the public domain. He also said the first convertivble offering would eventually have warrants attached which it did. Funny that he would know all this however, given both parties are based in San Francisco he probably overheard a converstion in his favourite bar the Monk's Kettle.
Given their exposure why don't HCM declare their stake? Or is it still in convertible form? Hve they sold any already?Lots of questions but no transparency! THat doesn't make for a very good partnership.
Incidentally HCM was a secret investor in Dendreon in 2008 which raised eyebrows because of its unusually generous terms ( 8m shares plus 8m free warrants). Strange that Dendreon was also subjected to media attacks from a familiar source as well.
One thing is for sure HCM are clearly not invested in this because they believe in the science or the potential.
They see it as a cash cow. On that note I also have serious misgivings that they are part of a company/group that trades and Market Makes in NWBO common stock and options. One has to beleive Chinese Walls are in place but given the unusual price action at key times it doesn't fill you with confidence.
Dendreon halved in the 12 months after HCM's investment from $5.75 to $2.50 before the FDA lit the blue touchpaper.
Anyone not suprised by the price action post the Woodford news? I am....but the upshot is, with 35m warrants out there, those expecting a sudden surge are likely be disappointed.
I am not so convinced German pricing news will be enough for a sustainable rally now.Not that I really care as I strongly believe this stock will win through in the end.
What this comapny needs now is a bulge bracket investment Bank to step up to the plate and offer full coverage.
Suggestions anyone? Less
Sentiment: Strong Buy
there are 35m warrants and not all of them have the same strike price and duration. Only one line is tradeable and there have been no announcement to say that any have be exercised.
Sabby and Heights Capital hold the lions share however, the Investment Banks that handled the placings took warrants as part payment too (certainly Oppenheimer)
Why do they issue warrants? Because the HF's hold a gun to their head . It means the funds appear to commit capital but effectively the warrants derisk it.
You beleive in the science like Woodford you dont resort to dirty tricks.
The warrants have will cast a shadow until the chance of success becomes overwhelming. That will hopefully be 2015.
Dendreon, similarly weighed down with warrants , shot from $2.75 to $50 on FDA approval.
Dendreon didn't hold that level for long for well documented reasons. Those reasons are why everyone will be celebrating Linda Powers foresight in future years. Everyone except AF of course! Less
Sentiment: Strong Buy
It's amazing that tumor storage isn't discussed more in the oncology field yet. Hopefully it will be SOC protocol someday. Bob Gibbs foundation has helped with this.
http://www.virtualtrials.com/newsarticle.cfm?item=4803
http://www.milesforhope.org/index.php/about-us-2
“All of this is only possible if the brain tumor tissue is saved and stored properly”, said Gibbs. Gibbs is the co-founder of Miles For Hope, a national organization who focuses on raising awareness of brain tumors and on funding cutting edge brain tumor research. “Many people contact us wanting to enroll in a vaccine clinical trial only after they already had their tumor removed. It is hard for us to tell them that they don’t qualify for these new treatments since the tumor tissue was either disposed of, or not stored properly for further use. Most hospitals will store a small sample of the patient’s brain tumor tissue in their pathology departments, but they typically use the tumor sample for their own research and will not give patients access to this tumor tissue once it’s removed and stored, treating the sample as the property of the hospital or facility where it was removed.
Love both comments
Milou2 • 3 days ago
Contrary to what you say, there is nothing "controversial" about NWBO's brain cancer drug ( an immuno therapy treatment actually). It is supported by UCLA and MD Anderson in the US, and King College in London, amongst many other world renowned institutions, with products in Phase II and Phase III clinical trials. In Germany, the Company has also received a 5 year Hospital Exemption for the treatment of all gliomas (train cancer) patients outside of the clinical trials. In Britain its product has been awarded "promising innovative medicine" status, thereby making it eligible for fast-track designation under a new early access program operated by the department of health that allows access to novel drugs before they are officially licensed for sale. With the validation conferred by this recent investment by the Woodford's Fund, the only thing that has been controversial is the way it has been bashed by your friends at The Street.com, along with many other junior biotech companies which are heavily shorted by financial outcasts. As you say, it takes a planet...
disqus_EBqabBLdqG • 3 days ago
"The move closely followed his decision to take a sizable stake in Bethesda, MD-based Northwest Biotherapeutics ($NWBO), which is developing a controversial brain cancer drug."
Controversial? Yes because shorts have realized they made wrong bet and thought they could do anything in deception, distortion and scaring off any long investors, a kind of Godfather like mentality without any conscience and shame for disrupting the powerful and so-far-very-successful development of company's DCVax platform, which can be used to treat both operable and inoperable cancers!
" Maryland-based Northwest has been doing much of its research work in Europe, scoring the U.K.'s first designation as a "Promising Innovative Medicine" that can earn fast-track review status."
Incorrect: Most development work has been done is in the United States of America. Despise that, it is the Germans and the Britons who have first recognized how advanced is the company's DCVax platform that has no a close rival in the world.
The success of DCVax platform will be no doubt a huge contribution to the mankind, and a huge benefit to tens of millions of cancer patients!
Would love if a bomb dropped on shorts
[quote The shorts continue to grow, could they all be wrong, doubt it.....maybe you over estimate Nwbo's science, regardless of what happens the shorts will get out in time, more than likely, because this company messes things up & the folks with the money are betting elsewhere with there money, not here.....True; Germany stepped up, but when the details come out, folks will be disappointed,these wildly speculative numbers on this board are humerous/quote]
This mentality on yahoo's board can be frustrating...but I trust the integrity and fortitude LP. What A Very, Very methodical approach the last few months have been. Of course ONLY poor clinical results will prove otherwise which I see as a low probability.
When a biotech investor of this caliber makes an investment into a company people/investors WILL PAY ATTENTION. This is going open the eyes of the many who have been skeptical of NWBO. Maybe not the same as the Baker Brothers but I think flame has been ignited and NWBO IS being "seen" now. (I was there for, and still am, the ACAD run).
Can't say enough about this boards intelligence and perseverance. Your hard work will be rewarded as will patients....worldwide??!!
How cool would that be??
Overcome the immuno-suppressive effects of tumors
"Investigators from MD Anderson and UCLA recently published an encouraging poster on DCVax Direct. The great challenge for immuno-oncology drugs is that tumors can evolve mechanisms that enable them to block or escape the immune response. One of the major arguments against cancer vaccines has been that they can’t overcome the immuno-suppressive effects of tumors in order to create an immune response.
Importantly, the authors of this paper concluded that DCVax Direct can overcome the ability of the tumor to block the immune response and make the tumor susceptible to the immune system. Imaging scans and biopsies, according to the investigators, show that DCVax Direct causes substantial infiltration of immune cells into the tumor which indicates that it is stimulating an immune response against the cancer. They further concluded that DCVax Direct is causing tumor cells to die and noted that some biopsies actually showed no live tumor cells. They also stated that injections into one local tumor mass (as was the protocol in this trial) were able to have an effect not only at the site of injection but also on metastases. This poster substantiates that DCVax Direct is causing a strong immune response that results in systemic effects against the tumor. This is very important.
We are likely to see further interim analysis for the phase1 portion of DCVax Direct trial in the next several quarters. The phase 1 portion of the trial will complete enrollment of 36 patients in 1Q, 2015. However, the design of the trial allows the phase 2 portion in 24 patients to begin before the phase 1 is completed. Northwest will announce the trial design in coming months and the disease target. This also has the potential to create investor enthusiasm and anxiety for shorts."
FROM Smith on Stocks article. Anxiety for shorts will be the understatement of the year 2015. Have a nice day!
Colon cancer support forum. Patients are learning about DCVax technology. Great to see this.
http://coloncancersupport.colonclub.com/viewtopic.php?f=1&t=46619
Maia,
I am highly needle-phobic. Can't stand to look at one. I had a needle biopsy on one breast years ago that was just a cyst, but haven't needed anything since then. I'm not sure I could describe the location of the various lung nodules I have, but I would think at least some of them would be difficult to get to. I know one is in the mediastinum, another in the left lingual area, and another near the top of the left lung. Since I have heard of lung nodules in locations too problematic to radiate, I just assumed that the location might cause problems for the vaccine injection. It would be nice to be wrong and have this as another thing to try down the road, although I haven't checked to see if the PD-L1 study excluded me from this also.
I'll worry about that another day.
Dianne
May 06 Stage IV CC: liver,ovarian mets
Oct 07 inoperable lung mets
Feb 08 - Apr'12 chemo
allergic to oxaliplatin, irinotecan
Aug '12-Feb'14 Genentech PD-L1/Avastin trial
Mar '14 -radiation to largest lung nodule
still recovering; looking at trials again
dianne052506 1651 Sun Nov 02, 2008 11:57 pm North Carolina
"Personally my interest in this technology is because of the concept of a dendritic cell vaccine. Ralph Steinman won a Nobel Prize in 2011 for his discovery of the role of dendritic cells in adaptive immunity. If one's own immune system can recognize and memorize the characteristics of cancer cells, then cancer would have a hard time to to take hold in one's body (Dendritic cell functions to teach the immune system to recognize other cells).
Past attempts of dendtritic cells cancer treatment involved the use of immature dendritic cells. What's different about DCVax-Direct is the dendtritic cells used here is partially matured then injected back into the tumor. Supposedly this will allow the DC cells to better pickup tumor antigens.
Since this technology is from a tiny development stage biotech company based in Maryland, it lacks the marketing prowess of a Merck or a Roche, so you won't hear much about it from the mainstream media. But in concept, the vaccine approach to cancer treatment is just as if not more promising than all the immune checkpoint inhibitors (PD-1/PD-L1, CTLA-4) that are all the buzz right now."
lichens 42 Tue Nov 13, 2012 12:46 pm
Vault Nanoparticles video.
New technology at UCLA, maybe a better way to deliver DCVAX-L. Sorry if has been posted, worth a look. Probably years away. Dr Liau and Bob Gibbs seen in video. UCLA looking like the leaders here
http://neurosurgery.ucla.edu/body.cfm?id=1276
[PDF]Abstract Submission Guidelines - SITC 29th Annual Meeting
(Google the above topic to pull the entire 3 page guideline)
Topic Areas
(Must select only one topic area per submission)
•
Adoptive Immunotherapy
•
Barriers to Successful Vaccines
•
Clinical Trials in Progress*
•
Coinhibition and Costimulation: Targets and Strategies
•
High Throughput Technologies: Determinants of the Immune Response to Cancer
•
Immune Monitoring*
•
Immunopotentiation by Radiotherapy: Mechanisms andOpportunities
•
Inflammation, Innate Immunity and Microbiome
•
Lung Cancer: Immunology & Immunotherapy
•
Metabolism and Molecular Targeted Therapies*
•
Tumor Microenvironment and Immunosuppression
*Denotes a poster-only category.
Abstracts submitted in these categories are eligible for poster
presentations only. However, all abstracts noted as
eligible for Young Investigator Travel Awards will be
considered for oral presentation during the Presidential Session as well as poster presentation.
Is NWBO eligible for this????
Wonderwoman would be jealous of her strength! We can't imagine going through the thoughts and feelings of her current state. ..friends and family are so important in life to say the least. Thanks sentiment
Jim Allison PhD at M.D. Anderson video
http://www.m.webmd.com/a-to-z-guides/video/video-cancer-immunotherapy
Nothing mentioned on DCVax but but the increased exposure to immunotherapy treatment OVER chemotherapy I think is very important.
Northwest Biotherapeutics technology cannot come fast enough as we all have been touched by cancer. This email (today) is from a dear friend of my wife's... I feel I can share it with this board as the knowledge of what's happening with immunotherapy here is astounding and much appreciated by myself.
"Friends,
My son ******* said it best to me this afternoon, the adventure truly starts when your original plans fall apart.
Today I learned there is a new phase to my recovery - - Chemotherapy. When the surgeon went in for my surgery two weeks ago, they noticed the cancer had spread outside the original contained area and chose not to do the original reconstruction as planned. I went from DCIS (ductal carcinoma in-situ) to DC Invasive. The cancer inside my duct was hormone receptive (which is good), the cancer outside my duct was Triple Negative (not as good and not receptive to hormone therapy). Because of this, the chance of reoccurrence grows significantly as the cancer can spread through my blood vessels and not just lymph nodes. Chemotherapy reduces the chance of reoccurrence to less than 10%. In the end it’s all about not ever having to deal with this ^&*% again.
The first treatment of 8 starts on November 20th…every other week. The good news . . .Doctor’s orders - - live life as you normally would and re-start my routine. That is what I intend to do. I received my release to come back to work and plan to do so on November 12th. Between now and then they said I can work remotely - - I’m going to start easing back into it but from my mountain house in **. Trust me, my seasonings are all alphabetized and my house is in total order J. I have rested, will continue to rest and I will take this next week to wrap my head around Phase 2.
The plan will be to do the Chemo on Thursdays every other week, and work from home on Fridays…..I’m healthy. I’m ready. I may just need to take a nap every now and then. Please trust that I will listen to my body and not put myself or our business at jeopardy. I have an amazing team at work, at home and I can’t wait to get back. I get to be a blonde, red head or maybe a baseball cap wearing girl for the next few months. A Bald ***** running around. A sight to see in the near future.
Appreciate all your support and look forward to seeing you all VERY soon. Feel free to share with your team and update them as you want. The support, love and encouragement I have received through all of this is more than words can express and can’t tell you all how much it has meant."
Combination therapies as mentioned in the video will be strong topics in the coming months. GLTA
Remember "The Perfect Storm" article??
http://smithonstocks.com/northwest-biotherapeutics-the-perfect-storm-may-be-brewing-for-short-sellers-nwbo-7-66-buy-free-content/
This looks more eminent than ever!!!
"Short sellers are extremely exposed to this stock"
Northwest Biotherapeutics: The Perfect Storm May Be Brewing for Short Sellers (NWBO, $7.66, Buy, Free Content)
Posted by Larry Smith on Jun 16, 2014 • (5)
I wrote on June 12th that NWBO stockholders may be seeing a changing in the tide of investor opinion. The release of an update on interim data on the phase 1 trial of DCVax Direct has had a major impact as the stock has increased 20% in the week since that release. Today, the Company announced that it has been added to the Russell Global and Russell 2000 Indexes which are benchmarks for an estimated $5.2 trillion of assets. This usually (always) results in significant buying for stocks added to the index.
Short sellers are extremely exposed to this stock with nearly 6.5 million shares sold short and I have heard that there may be an additional 2.0 million of naked short sales. The strong reaction to positive news on DCVax Direct and the addition to the Russell indexes have to be a major cause of concern and could lead to short covering and potentially a short squeeze.
More ominous clouds on the horizon for short sellers are a number of positive catalysts that could potentially arise through the balance of 2014. The largest drag on the stock has been speculation as to why there has been no mention of an interim efficacy analysis having been completed in the DCVax-L trial. The bears have suggested that this was because NWBO had seen the results, that they were negative and they were being purposely withheld from investors to prop up the stock price. This is ridiculous because NWBO is blinded and could only see the results if the trial were stopped for futility or for efficacy. Both are material events that would require an immediate press release.
It seems to me that the reason for this is that the Data Safety and Monitoring Board has not performed the analysis. The Company has suggested on several occasions that it might enlarge the trial of DCVax-L. I think if this was done that the DSMB would defer the interim analysis until the regulatory approvals for expansion were cleared. I think that the reason there has been no announcement on the efficacy analysis is that it hasn’t been done. My opinion seems to be a minority view but for me this seems the only logical conclusion. If I am right, we should hear in days, weeks or a month or two about this and the major pillar of the bear argument would be swept away.
We have not heard an update on the German hospital exemption early access program since the announcement in early March that DCVax-L had received approval from PEI (the German equivalent of FDA) and that it also had been placed on the list of drugs that are eligible for reimbursement. The logistics in preparing supplies of DCVax-L and seeking reimbursement are not matters that can be done in a few days or weeks.
I think that later in the year we will hear that the first patient(s) has been treated and that reimbursement has been negotiated with one of the regional health care providors. There has been some confusion among investors that this program is no more than an older compassionate use program that has been used in Europe for many years that usually requires an IND to be filed for each patient and sharply limits the number of patients that can be treated. The hospital exemption is very different and is not that different from a full approval. As this becomes clear to investors, I think that this will be seen widely for what it is: an extraordinarily positive event.
The Company has an approval for selling DCVax-L in the UK that is similar to that in Germany except that there is no potential for reimbursement from the UK national health insurance program. We may hear more about the UK once Germany begins to get up and running. Patients with adequate resources can pay for and gain access to DCVax-L in the UK.
The German and UK programs could result in a product sales revenue line this year. For an emerging biotechnology firm, realizing revenues is a major positive event.
The Company will continue to release interim data on the open label phase 1 trial of DCVax Direct. If the initial results which have been so encouraging are durable, this could also be a significant positive. There seems little question that we are seeing a biological effect with the drug, but the issue will be whether the effect is lasting.
I think that there is the potential for a major short squeeze given all of these events and how strung out the shorts are. I would also add that hedge funds are like sharks in a feeding frenzy and if other hedge funds see the hedge funds currently short the stock getting squeezed, they will jump in and exacerbate the squeeze. This is why I see a perfect storm building that could cause the stock to over react on the upside. This could create a difficult decision for long term investors but I will cross that bridge when we get to it.
Tagged as dcvax direct, DCVax-L, German hospital exemption early access, Northwest Biotherapeutics Inc., NWBO + Categorized as Smith On Stocks Blog
Great article Pyrr!!!
"In particular, and in regards to progression-free survival (PFS), which is the primary endpoint in the Ph III DCVax-L trial, they noted:
Information on the 1-, 1.5-, and 2-year PFS was available for two trials, which contained 145 patients (30 patients received DC immunotherapy). DC immunotherapy led to a 1-, 1.5-, and 2-year PFS of 70%, 50%, and 37% (21/30, 15/30 and 11/30), respectively, in HGG patients who received DC treatment, whereas the 1-, 1.5-, and 2-year PFS in the controls was only 32%, 15%, and 3% (37/115, 17/115, and 4/115), respectively.
Both of the trials showed a longer disease-free survival for patients who received DC immunotherapy in comparison to the historical or randomized cohorts at one, one and a half and two years. The estimated pooled OR for the two trials showed a highly significantly improved one, one and a half, and two-year PFS for patients receiving DC immunotherapy.
In other words, more than double the effectiveness of SOC alone at 1 year, over 3x as effective out to 1.5 years, and over 10x as effective out to 2 years. That is astounding, especially when considering the only advancement in decades was Temodar back in 2005 (now generic temozolomide), which added a meager 2.6 months overall survival to surgery and radiation alone."
If MD Anderson Cancer Center/DR. Vivek Subbiah, MD verifies this next week then game over IMHO. Best message board I've ever read here BTW...Great job everyone
Corporate presentation in UK worth another listen.